Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. ; (2), KIM MS et al. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. (). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Stereotactic Slotman B, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. SLOTMAN B, SENAN S. Experiences of case managers in providing. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Radiobiological. Quality of life. Slotman BJ, van Tinteren H, Praag JO, et al. . Kim, & Blakeney, ). Radiother. Treatment of stage I NSCLC in elderly patients: a. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Kumar,. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.